37 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
7 Jun 18
Zafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
5:06pm
look forward to being part of the Zafgen Board of Directors as the Company advances its novel clinical development programs and works to meet its R&D, patient … , Zafgen
John LaMattina, Ph.D., Former President of Pfizer Global R&D
C. Geoffrey McDonough, M.D., President and Chief Executive Officer, Generation Bio
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
, Finance, Marketing, Corporate and R&D organizations. During his15-year tenure in the Business Development organization he personally led the assessment … and advisement to his team on the execution of over 100 global business development transactions. He also managed GSK’s portfolio of R&D equity investments
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
11 Mar 19
Results of Operations and Financial Condition
4:12pm
a decade of senior drug development
experience in R&D strategy, drug safety and benefit-risk management. Dr. Singhal is responsible for leading … an invaluable depth of R&D expertise and leadership to Zafgen and is ideally suited to drive efforts across all our key areas of focus. We are so thrilled
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
30 May 19
Zafgen Announces Regulatory Update onZGN-1061
7:21am
team, Dr. Priya Singhal, our new Head of R&D, and Lisa Percival, our Vice President of Regulatory,” said Jeffrey Hatfield, Chief Executive Officer
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
9 May 19
Zafgen Reports First Quarter 2019 Operating and Financial Results
4:26pm
team, Priya Singhal, M.D., M.P.H., as Head of Research and Development, who brings nearly a decade of senior drug development experience in R&D strategy
8-K
EX-99.2
4uflwi
10 Nov 20
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results
4:23pm
10-K/A
p1l2qls9e1gwb3ax
29 Apr 16
Annual report (amended)
12:00am
8-K
EX-99.1
ih8us6r x3fxk
8 Dec 20
Regulation FD Disclosure
7:40am
PRE 14A
2izscswukqn5vv6
12 Apr 24
Preliminary proxy
6:06am
8-K
EX-99.1
whq u1fgu
20 Oct 22
October 2022 Larimar Therapeutics Corporate Presentation
8:11am
8-K
EX-99.1
wuhef ru1dmmmio6i
1 Jul 21
Other Events
6:11am
8-K
EX-99.1
ox91 69he
14 Jun 21
Other Events
5:21pm
8-K
EX-99.2
acmd59 ek0cb
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.2
4ybh sxqy
14 Sep 22
Other Events
7:05am
8-K
EX-99.1
a96gjf6
28 Feb 22
Results of Operations and Financial Condition
8:16am
8-K
EX-99.2
kjarj5s6gyw44zxsu0
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
8-K
EX-99.1
y1om04zvkt84qxks1j
18 May 21
Other Events
3:09pm